See more : Union Metallurgique de la Haute-Seine S.A. (MLUMH.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Dyadic International, Inc. (DYAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dyadic International, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Iberdrola, S.A. (IBE1.BE) Income Statement Analysis – Financial Results
- Ebara Corporation (6361.T) Income Statement Analysis – Financial Results
- Mivne Real Estate (K.D) Ltd (MVNE.TA) Income Statement Analysis – Financial Results
- Sun Corporation (6736.T) Income Statement Analysis – Financial Results
- American Aires Inc. (AAIRF) Income Statement Analysis – Financial Results
Dyadic International, Inc. (DYAI)
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.90M | 2.93M | 2.40M | 1.60M | 1.68M | 1.30M | 758.42K | 592.89K | 315.71K | 12.52M | 17.13M | 15.60M | 15.38M | 15.88M | 16.74M | 211.27K |
| Cost of Revenue | 1.98M | 2.12M | 1.94M | 1.42M | 1.46M | 1.03M | 680.20K | 516.16K | 124.01K | 8.18M | 9.72M | 7.62M | 11.35M | 12.86M | 12.83M | 175.44K |
| Gross Profit | 922.96K | 807.11K | 459.39K | 176.99K | 221.38K | 268.17K | 78.22K | 76.72K | 191.70K | 4.35M | 7.41M | 7.99M | 4.04M | 3.03M | 3.91M | 35.83K |
| Gross Profit Ratio | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.70% | 10.31% | 12.94% | 60.72% | 34.71% | 43.25% | 51.18% | 26.25% | 19.05% | 23.34% | 16.96% |
| Research & Development | 3.30M | 4.50M | 8.39M | 3.87M | 3.96M | 3.32M | 2.20M | 885.60K | 124.01K | 2.19M | 1.00M | 921.71K | 4.24M | 4.90M | 3.62M | 0.00 |
| General & Administrative | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 6.11M | 4.99M | 4.48M | 7.15B | 5.32M | 3.76M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 944.12K | 700.78K | 3.42B | 2.81M | 1.86M | 0.00 |
| SG&A | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 7.36M | 5.94M | 5.50M | 10.57M | 8.13M | 5.61M | 42.54K |
| Other Expenses | 38.42K | 250.00K | 6.09M | 187.39K | 2.30M | 2.04M | 220.72K | 436.92K | 0.00 | 0.00 | 0.00 | 0.00 | -28.70K | -16.79K | 0.00 | 184.07K |
| Operating Expenses | 9.15M | 10.92M | 15.09M | 10.14M | 9.48M | 7.84M | 7.45M | 5.88M | 3.84M | 9.55M | 6.94M | 5.87M | 14.77M | 13.01M | 9.24M | 226.61K |
| Cost & Expenses | 11.13M | 13.05M | 17.03M | 11.57M | 10.94M | 8.87M | 8.13M | 6.40M | 3.96M | 17.72M | 16.66M | 13.49M | 26.12M | 25.87M | 22.07M | 402.05K |
| Interest Income | 416.69K | 180.42K | 51.70K | 447.00K | 984.93K | 0.00 | 0.00 | 485.49K | 11.16K | 28.06K | 14.61K | 695.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 894.53K | 566.15K | 909.00 | 11.16K | 683.21K | 686.02K | 0.00 | 594.16K | 710.54K | 597.91K | 0.00 |
| Depreciation & Amortization | 0.00 | 10.12M | 3.49M | 9.96M | 9.25M | 7.40M | 7.38M | 5.81M | -2.17M | 271.13K | 253.50K | 256.48K | 250.18K | 602.73K | 586.69K | 0.00 |
| EBITDA | -8.23M | -10.07M | -13.07M | -10.19M | -9.23M | -7.55M | -2.20M | 0.00 | -5.82M | -5.45M | 726.69K | 1.82M | -9.91M | -9.13M | -4.87M | -190.78K |
| EBITDA Ratio | -283.90% | -343.51% | -671.40% | -635.84% | -548.88% | -582.88% | -1,580.02% | -897.71% | -1,842.27% | -39.11% | 4.33% | 11.65% | -71.47% | -60.63% | -27.04% | -90.30% |
| Operating Income | -8.23M | -10.12M | -14.73M | -10.03M | -9.28M | -7.59M | -7.13M | -5.96M | -3.65M | -5.32M | 556.50K | 1.56M | -10.74M | -9.99M | -5.33M | -190.78K |
| Operating Income Ratio | -283.90% | -345.21% | -612.67% | -625.85% | -552.18% | -586.09% | -939.70% | -1,004.45% | -1,154.93% | -42.52% | 3.25% | 10.00% | -69.78% | -62.87% | -31.82% | -90.30% |
| Total Other Income/Expenses | 1.43M | 430.42K | 1.66M | 731.71K | 984.93K | 894.53K | 4.92M | 2.58M | 2.18M | 47.81K | -984.55K | -142.86K | -41.87K | -442.94K | -725.71K | 190.78K |
| Income Before Tax | -6.80M | -9.74M | -13.07M | -9.29M | -8.30M | -6.70M | -2.20M | -3.37M | -1.47M | -5.98M | -428.05K | 1.42M | -10.82M | -10.45M | -6.07M | 0.00 |
| Income Before Tax Ratio | -234.42% | -332.23% | -543.73% | -580.18% | -493.59% | -517.03% | -290.41% | -568.52% | -464.06% | -47.75% | -2.50% | 9.09% | -70.33% | -65.80% | -36.26% | 0.00% |
| Income Tax Expense | 0.00 | -364.37K | -148.60K | 31.32K | 10.31K | -1.01M | -66.69K | 238.07K | -69.44M | 127.39K | 229.83K | 68.00K | 63.11K | 64.23K | 9.71K | 190.78K |
| Net Income | -6.80M | -9.37M | -12.92M | -9.33M | -8.31M | -5.69M | -2.14M | -3.61M | 65.79M | -5.98M | -428.05K | 1.35M | -10.88M | -10.51M | -6.08M | -190.78K |
| Net Income Ratio | -234.42% | -319.79% | -537.54% | -582.13% | -494.21% | -439.36% | -281.61% | -608.67% | 20,837.76% | -47.75% | -2.50% | 8.65% | -70.74% | -66.20% | -36.32% | -90.30% |
| EPS | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.42 | -0.04 |
| EPS Diluted | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 33.74M | 24.42M | 22.13M | 14.39M | 5.00M |
| Weighted Avg Shares Out (Dil) | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 34.23M | 24.42M | 22.13M | 16.32M | 5.00M |
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows:
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its...
Dyadic to Attend Industry Events in March
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel...
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical...
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Source: https://incomestatements.info
Category: Stock Reports